Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
JNJ-64042056 · 1 trial · 1 indication
Change from baseline in brain tau burden, as measured by tau PET (including but not limited to Braak I-VI ROIs, tau naive composite ROI, Connection Rank ROI, and New Tau Composite ROI Volume) will be reported.
| Arm | Type | Description |
|---|---|---|
| Arm A: JNJ-64042056 | EXPERIMENTAL | Participants will receive intramuscular (IM) injection of JNJ-64042056 from Week 0 up to a maximum of Week 76. |
| Arm B: Placebo | PLACEBO_COMPARATOR | Participants will receive IM injection of placebo from Week 0 up to a maximum of Week 76. |
| Name | Type | Description |
|---|---|---|
| JNJ-64042056 | DRUG | JNJ-64042056 will be administered intramuscularly. |
| Placebo | DRUG | Placebo will be administered intramuscularly. |
Inclusion Criteria: * Elevated brain tau pathology defined as Braak 3 region of interest standardized uptake value ratio (ROI SUVR) greater than (\>) 1.1 (or equivalent based on emerging data) on a screening tau PET scan, reviewed centrally by a qualified reader to enrich for probability of disease...
Top 20 of 25 competitors